[Blood amino acid composition of bronchial asthma patients undergoing therapy with immunodepressants and cytostatics].
It has been revealed that bronchial asthma (BA) running a moderate and severe course is characterized in the phase of exacerbation by marked hypodysaminoacidemia. The cytostatics 6-mercaptopurine and azathioprin in doses of 1.5-2 mg/day per kg bw (the total treatment dose 2000-4000 mg) aggravate the initial hypodysaminoacidemia in this patient population, resulting in the lowering of the treatment efficacy and body responsiveness. During cytostatic treatment of BA patients, it is necessary to include the drugs having anabolic and immunomodulating properties into multiple modality treatment. The short-term results of cytostatic therapy were fairly good in 10%, good in 25%, satisfactory in 50%, and unsatisfactory in 15% of patients. The long-term results (14-38 months) were worse: there were no fairly good results, good results were attained in 10%, satisfactory in 20%, and unsatisfactory in 70% of patients. No hematological complications were recorded. Azathioprin was tolerated better than 6-mercaptopurine.
D000293:Adolescent; D000328:Adult; D000368:Aged; D000596:Amino Acids / Q000097:blood*; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001249:Asthma / Q000097:blood* / Q000188:drug therapy; D001322:Autoanalysis; D002908:Chronic Disease; D004341:Drug Evaluation; D005260:Female; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D013997:Time Factors
D000596:Amino Acids; D000970:Antineoplastic Agents; D007166:Immunosuppressive Agents
Aminokislotnyĭ sostav krovi u bol'nykh bronkhial'noĭ astmoĭ na fone terapii immunodepressantami-tsitostatikami.